Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) will release earnings results for its fourth quarter, before the opening bell on Friday, Jan. 30.
Analysts expect the Tarrytown, New York-based company to report quarterly earnings at $10.74 per share, down from $12.07 per share in the year-ago period. The consensus estimate for Regeneron Pharmaceuticals’ quarterly revenue is $3.79 billion, versus $3.79 billion a year earlier, according to data from Benzinga Pro.
On Dec. 1, Regeneron Pharmaceuticals and Tessera Therapeutics, Inc., announced a global collaboration to develop and commercialize TSRA-196.
Regeneron Pharmaceuticals shares fell 0.2% to close at $749.44 on Thursday.
Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let’s have a look at how Benzinga’s most-accurate analysts have rated the company in the recent period.
- Evercore ISI Group analyst Cory Kasimov maintained an Outperform rating and raised the price target from $750 to $875 on Jan. 22, 2026. This analyst has an accuracy rate of 68%.
- Truist Securities analyst Gregory Renza maintained the stock with a Buy rating and raised the price target from $798 to $820 on Jan. 8, 2026. This analyst has an accuracy rate of 58%.
- B of A Securities analyst Tazeen Ahmad upgraded the stock from Underperform to Buy and boosted the price target from $627 to $860 on Jan. 7, 2026. This analyst has an accuracy rate of 59%.
- Morgan Stanley analyst Matthew Harrison maintained an Equal-Weight rating and increased the price target from $767 to $768 on Dec. 12, 2025. This analyst has an accuracy rate of 61%.
- Wells Fargo analyst Mohit Bansal maintained an Equal-Weight rating and boosted the price target from $700 to $745 on Dec. 10, 2025. This analyst has an accuracy rate of 69%.
Considering buying REGN stock? Here’s what analysts think:
Photo via Shutterstock
Recent Comments